X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES LUPIN LTD ALKEM LABORATORIES/
LUPIN LTD
 
P/E (TTM) x - 19.9 - View Chart
P/BV x 7.4 2.7 275.0% View Chart
Dividend Yield % 0.6 0.9 62.9%  

Financials

 ALKEM LABORATORIES   LUPIN LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
LUPIN LTD
Mar-17
ALKEM LABORATORIES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,5891,750 90.8%   
Low Rs1,2321,384 89.0%   
Sales per share (Unadj.) Rs417.5387.4 107.8%  
Earnings per share (Unadj.) Rs56.356.6 99.4%  
Cash flow per share (Unadj.) Rs64.776.8 84.2%  
Dividends per share (Unadj.) Rs12.707.50 169.3%  
Dividend yield (eoy) %0.90.5 188.1%  
Book value per share (Unadj.) Rs292.9298.9 98.0%  
Shares outstanding (eoy) m119.57451.58 26.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.44.0 83.5%   
Avg P/E ratio x25.127.7 90.6%  
P/CF ratio (eoy) x21.820.4 106.9%  
Price / Book Value ratio x4.85.2 91.9%  
Dividend payout %22.613.2 170.4%   
Avg Mkt Cap Rs m168,653707,513 23.8%   
No. of employees `000NA16.8 0.0%   
Total wages/salary Rs m9,17128,495 32.2%   
Avg. sales/employee Rs ThNM10,418.3-  
Avg. wages/employee Rs ThNM1,697.0-  
Avg. net profit/employee Rs ThNM1,523.0-  
INCOME DATA
Net Sales Rs m49,915174,943 28.5%  
Other income Rs m1,6451,065 154.5%   
Total revenues Rs m51,561176,008 29.3%   
Gross profit Rs m8,48244,931 18.9%  
Depreciation Rs m1,0069,122 11.0%   
Interest Rs m6711,525 44.0%   
Profit before tax Rs m8,45135,349 23.9%   
Minority Interest Rs m-114-72 158.7%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6069,785 16.4%   
Profit after tax Rs m6,73125,575 26.3%  
Gross profit margin %17.025.7 66.2%  
Effective tax rate %19.027.7 68.7%   
Net profit margin %13.514.6 92.2%  
BALANCE SHEET DATA
Current assets Rs m27,062119,542 22.6%   
Current liabilities Rs m15,32461,206 25.0%   
Net working cap to sales %23.533.3 70.5%  
Current ratio x1.82.0 90.4%  
Inventory Days Days6776 87.5%  
Debtors Days Days4190 45.9%  
Net fixed assets Rs m12,610131,660 9.6%   
Share capital Rs m239903 26.5%   
"Free" reserves Rs m34,490134,073 25.7%   
Net worth Rs m35,027134,976 26.0%   
Long term debt Rs m1,21256,478 2.1%   
Total assets Rs m54,387266,073 20.4%  
Interest coverage x13.624.2 56.3%   
Debt to equity ratio x00.4 8.3%  
Sales to assets ratio x0.90.7 139.6%   
Return on assets %13.610.2 133.6%  
Return on equity %19.218.9 101.4%  
Return on capital %24.919.3 129.0%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56381,885 8.0%   
Fx outflow Rs m3,01221,506 14.0%   
Net fx Rs m3,55260,378 5.9%   
CASH FLOW
From Operations Rs m7,25941,148 17.6%  
From Investments Rs m1,864-25,287 -7.4%  
From Financial Activity Rs m-9,2734,332 -214.1%  
Net Cashflow Rs m-15020,193 -0.7%  

Share Holding

Indian Promoters % 66.9 46.6 143.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 33.1 11.3 292.9%  
FIIs % 0.0 31.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.1 -  
Shareholders   68,381 98,259 69.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NOVARTIS  ASTRAZENECA PHARMA  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS